De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PharmaCyte Biotech Dividend

Dividend criteriumcontroles 0/6

PharmaCyte Biotech heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

n/a

Uitbetalingsratio

Gemiddelde opbrengst industrie	1.9%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Winst per aandeel	US$0.59
Dividendrendementsvoorspelling	n/a

Recente dividendupdates

Geen updates

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van PMCB in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van PMCB zijn gestegen.

Dividendrendement versus markt

PharmaCyte Biotech Dividendrendement versus markt

Hoe verhoudt PMCB dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (PMCB)	n/a
Markt onderkant 25% (US)	1.4%
Markt Top 25% (US)	4.4%
Gemiddelde industrie (Biotechs)	1.9%
Analist prognose (PMCB) (tot 3 jaar)	n/a

Opmerkelijk dividend: Het dividendrendement van PMCB kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van PMCB kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio PMCB te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat PMCB geen uitbetalingen heeft gerapporteerd.

PharmaCyte Biotech Dividend

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente dividendupdates

Recent updates

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

PharmaCyte Biotech, Inc. announced delayed annual 10-K filing

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for 7,750,000 shares, for $25.19 million.

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

PharmaCyte Biotech, Inc. Announces Management Changes

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech, Inc. Announces Board Appointments

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Iroquois Capital Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech

PharmaCyte Biotech, Inc. Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Iroquois Capital Commences Consent Solicitation to Reconstitute Pharmacyte Biotech Board of Directors

Iroquois Capital Issues a Statement in Response to Pharmacyte Biotech

Iroquois Capital Delivers Open Letter to Pharmacyte Biotech Board of Directors

PharmaCyte Biotech, Inc., Annual General Meeting, Aug 25, 2022

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Initiates Studies to Confirm its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. Appoints Matthias Löhr to the Board

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech, Inc. Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Pharmacyte Biotech, Inc. Study Proves Capsule Material Is Not Toxic for Encapsulated Cells

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech, Inc. Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech, Inc. Announces Encapsulation Material Does Not Alter Cellular DNA

Pharmacyte Biotech, Inc. Releases More Positive Results from U.S. Food and Drug Administration-Required Biocompatibility Tests

Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

PharmaCyte Biotech: Buy The 'Dump'

PharmaCyte Biotech Common Stock Deleted from Other OTC

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. Announces Update on Study Progress

PharmaCyte Biotech, Inc. Announces Stability Test Results on Cells from Master Cell Bank

PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for Its Clinical Trial Product

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for Its Clinical Trial Product

PharmaCyte Biotech, Inc. Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. Announces Dr. Gerald W. Crabtree Will No Longer Serve as Chief Operating Officer But Instead Will Serve as Chief Scientific Officer

U.S. FDA Places PharmaCyte Biotech, Inc.’s Investigational New Drug Application on Hold

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. Successfully Completes Six-Month Stability Study

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend